Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,646 total articles
Erasca Chief Medical Officer Shannon Morris exercised 20,000 stock options and sold 20,000 shares on March 4, 2026, generating $300,760 in proceeds. The option exercise and sale were executed under a pre-planned Rule 10b5-1 program. The transactions occurred while Erasca shares trade close to their 52-week high and follow a sizable public offering …
InterDigital Chief Technology Officer Rajesh Pankaj disposed of 1,000 shares on March 5, 2026, at $368.10 per share, yielding $368,100. The sale was conducted under a Rule 10b5-1 trading arrangement adopted March 20, 2025. After the transaction, Pankaj directly holds 60,196.0702 shares. The stock is trading at $363.74, up roughly 75% over the last …
Elevance Health director Steven H. Collis purchased 3,000 shares on March 5, 2026, for $289.84 each, a transaction valued at $869,519. The trade comes as Elevance faces planned sanctions from CMS affecting Medicare Advantage-Prescription Drug enrollment and communications, a reorganization elevating CFO Mark Kaye to oversight of Carelon, and report…
Two substantial holders of ClearOne Inc. common stock disclosed a joint insider purchase on March 2, 2026, acquiring 437,500 shares at $4.00 per share for a total of $1.75 million. The transaction was reported by First Finance Ltd. and Andrew Hromyk, each identified as ten percent owners. The move comes against a backdrop of a 58% share price decli…
A director of Hercules Capital, Inc. (NASDAQ:HTGC) purchased 3,050 shares on March 4, 2026, for $14.78 each, a transaction that raised the director's direct holding to 19,560 shares. The filing shows the purchase was executed through the dividend reinvestment plan and was signed by an attorney-in-fact on March 5, 2026. The transaction comes amid co…
ResMed director Peter C. Farrell sold 2,000 shares on March 4, 2026, for $260.22 per share, totaling $520,440. The transaction occurred under a Rule 10b5-1 plan adopted August 12, 2025. ResMed reported fiscal second-quarter 2026 earnings per share of $2.81, ahead of the $2.73 analyst estimate, while revenue of $1.4 billion matched forecasts. Severa…
Healthcare Realty Trust Executive Vice President and CFO Daniel Gabbay purchased 10 shares of common stock on March 4, 2026, at $18.74 per share for a total of $187. The transaction leaves him with 191,158 directly held shares and 10 indirectly held shares through a child. The company reported fourth-quarter 2025 results that beat EPS expectations …
Peter Doyle, co-portfolio manager of RENN Fund, Inc. (RCG), purchased 200 shares on March 4, 2026, at $2.92 per share for a total of $584. The transaction leaves Doyle with 900 shares held directly and an additional 13,334 shares held indirectly through a spouse. The fund is trading close to a 52-week high and shows recent gains and a low P/E by th…
Esam Elashmawi, Senior Vice President of Marketing and Strategy at Lattice Semiconductor, sold 38,000 shares on March 4, 2026, under a prearranged 10b5-1 trading plan adopted December 3, 2025. The dispositions generated $3,494,319 in proceeds. The transactions occurred across multiple price points and left Elashmawi with 161,192 shares directly hel…
Hercules Capital Chief Operating Officer Christian Follmann bought 5,000 shares on March 4, 2026, spending $73,400 at an average price of $14.68. The purchase increases his direct stake to 150,135 shares. The company shows a rising NAV estimate and offers a high dividend yield, while analysts and a short seller flagged software exposure and dividen…
Tarsus Pharmaceuticals Chief Operating Officer Neervannan Seshadri disposed of 8,366 shares on March 4, 2026, realizing $641,421 at $76.67 per share. The transaction was made under a Rule 10b5-1 trading plan adopted last November. The move coincides with recent quarterly results showing substantial product-driven revenue growth, while the stock tra…
Jason D. Phillips, Chief Accounting Officer & Controller at Moody’s Corporation, sold 333.123 shares of common stock on March 4, 2026, generating $157,437 in proceeds. Following the sale Phillips retains 2,097.9505 shares. Moody’s reported fourth-quarter results that exceeded expectations, driven by its ratings and analytics businesses, prompting a…
Eric D. Chewning, executive vice president at Huntington Ingalls Industries, disposed of 1,700 shares on March 4, 2026, for $736,848. The transaction was reported in a Form 4 filing with the SEC. The sale comes as HII shares have risen 121% over the last year and after the company posted better-than-expected fourth-quarter 2025 results and drew rev…
Torran B. Nixon, Senior Executive Vice President at Columbia Banking System, INC. (NASDAQ: COLB), sold a total of 4,481 shares on March 3 and March 4, 2026, under a pre-established 10B5-1 trading plan. The transactions totaled $127,932. Columbia Banking trades near $28, carries a P/E of 12.13, and yields 5.29%, while several analysts raised price t…
Andrew Callos, Executive Vice President and Chief Commercial Officer at Cytokinetics (CYTK), sold 26,000 shares on March 5, 2026, for roughly $1.6 million and exercised options to acquire 26,000 additional shares the same day. The transactions leave Callos with 50,440 shares directly held. Analysts maintain optimistic price targets even as the comp…
United Therapeutics director Christopher Causey sold 20 shares of UTHR on March 4, 2026, for $9,803 and simultaneously exercised options to buy 20 shares at $119.76. The transactions were executed under a pre-arranged Rule 10b5-1 plan. The stock is trading near its InvestingPro Fair Value after a 58% year-over-year gain. Several analysts have raise…
Zebra Technologies Chief Marketing Officer Robert John Armstrong Jr. reported multiple equity transactions in early March 2026, including a sale of 9 Class A shares for $2,067 and separate purchases and exercises. The moves coincide with Zebra’s Q4 2025 results that matched EPS expectations and slightly exceeded revenue forecasts, while the stock h…
Karen M. Bick, Ralliant Corp's Senior Vice President and Chief People Officer, executed a planned share sale in early March 2026 and completed additional withholding transactions to satisfy tax obligations. The trades come against a backdrop of a large non-cash goodwill impairment, analyst price-target reductions, the opening of a new global headqu…
Figma, Inc. General Counsel and Secretary Brendan Mulligan sold 4,817 shares of Class A common stock on March 3, 2026, for $136,303 under a pre-established trading plan. The company reported a strong fourth quarter and raised fiscal 2026 revenue guidance, even as some analysts cut price targets citing valuation and AI-related margin pressure.
Boeing director Buckley Mortimer J. bought 2,230 shares of company stock on March 3, 2026, investing roughly $499,966 at $224.20 per share and bringing his direct holdings to 4,430 shares. The transaction comes amid a 40% year-over-year share price gain and analysis indicating the stock is trading above its Fair Value. Operationally, Boeing deliver…
Anne Mary Giviskos, Senior Vice President, Strategic Finance and Chief Accounting Officer at Navan, Inc., sold 31,150 shares of Class A common stock on March 3, 2026 to satisfy tax withholding on vested restricted stock units. The sale generated about $296,600 and left Giviskos with 74,940 shares. The company has pursued product enhancements, new o…
Home Depot Executive Vice President and Chief Financial Officer Richard V. McPhail reported the sale of 2,550 shares of common stock on March 4, 2026, for $368.89 per share, totaling $940,669. The transaction leaves McPhail with 44,566.4629 shares directly held. The sale occurred as Home Depot shares trade below their 52-week high and after a serie…
Rimini Street Executive Vice President and CFO Michael L. Perica sold 3,140 shares on March 3, 2026, for roughly $11,676 and exercised options on 6,667 restricted stock units. Separately, Rimini Street has broadened its engagement with Tidewater Inc., moving from a Brazil-focused Oracle PeopleSoft engagement to global support including SAP systems …
Klaviyo Chief Legal Officer Edmond Landon sold 15,093 shares of Series A common stock on March 5, 2026, for about $304,274 under a Rule 10b5-1 trading plan adopted last August. After the sale Landon directly holds 326,728 Klaviyo shares, including 228,407 unvested RSUs. The move comes amid a 44% year-over-year decline in Klaviyo shares, the company…
Klaviyo Co-CEO Andrew Bialecki sold 200,000 shares of Series A common stock on March 3, 2026, for $3,727,861 in total across multiple transactions. The filing also shows he converted 200,000 Series A shares into Series B stock the same day. The company announced a $500 million buyback program including an immediate $100 million accelerated repurcha…
